Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Rituximab Combined With CHOP For Successful Treatment of Aggressive Recurrent, Pediatric B-Cell Large Cell Non-Hodgkin's Lymphoma

Jetsrisuparb, Arunee MD*; Wiangnon, Surapon MD*; Komvilaisak, Patcharee MD*; Kularbkaew, Churairat MD; Yutanawiboonchai, Wiboonchai MD; Mairieng, Emorn MD

Journal of Pediatric Hematology/Oncology: April 2005 - Volume 27 - Issue 4 - p 223-226
doi: 10.1097/01.mph.0000158089.92165.a8
Clinical and Laboratory Observations
Buy

This report is the first to describe the successful treatment of a 14-year-old boy with aggressive recurrent, CD20-positive, B-cell large cell non-Hodgkin's lymphoma. The patient responded to three 4-week courses of rituximab (MabThera) given every 6 months and six cycles of CHOP given every 3 weeks in addition to a modified BFM 86 protocol. Transient neutropenia and lymphopenia occurred but with no clinical significance. The boy has been disease-free for the last 48 months (after 64 months of follow-up); his organ functions are normal. Rituximab and CHOP in addition to chemotherapy may be an alternative treatment for aggressive recurrent, pediatric CD20-positive B-cell large cell non-Hodgkin's lymphoma if highly intensive chemotherapy and stem cell transplantation are not available.

From the *Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; †Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; and ‡Department of Radiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

Received for publication July 15, 2004; accepted January 25, 2005.

Reprints: Arunee Jetsrisuparb, Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand (e-mail: arujet@kku.ac.th).

© 2005 Lippincott Williams & Wilkins, Inc.